This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Smith, Sonali
| Item Type | Name |
|
Concept
|
Burkitt Lymphoma
|
|
Concept
|
Lymphoma, Follicular
|
|
Concept
|
Lymphoma
|
|
Concept
|
Lymphoma, Mantle-Cell
|
|
Concept
|
Lymphoma, B-Cell
|
|
Concept
|
Lymphoma, Large B-Cell, Diffuse
|
|
Concept
|
Lymphoma, Non-Hodgkin
|
|
Academic Article
|
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
|
|
Academic Article
|
Something old, something new....
|
|
Academic Article
|
Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906.
|
|
Academic Article
|
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
|
|
Academic Article
|
Reduced-intensity transplantation for lymphoma.
|
|
Academic Article
|
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.
|
|
Academic Article
|
Targeting mTOR in mantle cell lymphoma: current and future directions.
|
|
Academic Article
|
Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.
|
|
Academic Article
|
Nonmyeloablative transplantation for lymphoma.
|
|
Academic Article
|
New drugs for the treatment of non-Hodgkin lymphomas.
|
|
Academic Article
|
Maintenance rituximab revisited: is it worth the cost?
|
|
Academic Article
|
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).
|
|
Academic Article
|
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
|
|
Academic Article
|
Too much and not enough: revisiting maintenance rituximab in indolent lymphomas.
|
|
Academic Article
|
Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges.
|